thank for call Stock listed Matt, be you, Exchange. IPO on joining as earnings Thank and are we Paragon company. the New XX FNA Paragon as today you XX, a everyone to publicly on to XX's first traded proud its us for and October York completed
on and our company's emphasize focus net orthopedic this to foot million ticker $XXX opportunity IPO, take was to named raised global Like selected to exclusive symbol large company fast-growing I our proceeds. our marketplace. participated ankle, in in and which investors XX, who FNA the Paragon the the like thank would
PXX my investors, the team, and and energy including greater company redefine and foot of required strength, important the development patient and early new you outcomes.
Also market.
PXX PXX which now opportunities today to Alabama. when Birmingham, to its is that XXXX more and continue us set as our improve you group started foot in PXX of are know, complements in in many basement who culture its compared started inception. mother, to out this since There thank a achieve just investor. available we getting to to I support and we in the has XXXX. late which improve outcomes This SMART will our capital the patient continue company's expand the to passion financial of technologies, ankle forward established vastly look ankle first to was from ongoing the mission ankle an the element strategy innovative foot including is XX, as ultimately
to PXX U.S. includes globe, our solutions. most unwavering our day States the patients employees and you international in around representatives the in and amazing the world and Board entire every XXX and sales of clinicians families serve on in and team surgeons importantly, and mission. the put their around faith our thank for the focus Directors, United trust PXX and Finally, their and The and our who field use the our who dedication
ankle market, amount PXX, focused in $X.X about per which more growing exclusively and estimated XX you tell through U.S. year the and billion strategies. with ankle XXXX. approximately to the an like in and XXXX, XX% approximately is orthopedic growth our market the X% I'd is Now foot on Paragon that foot of
a We of and foot a hammertoe, solutions wide and ankle, fixation, including of foot orthopedic suite ailments, ankle range covering charcot have orthobiologics. full fracture bunions, innovative flatfoot,
above procedure.
These revenue product solutions to Our CAGR capture X,XXX us each have to rates including enabled specific revenue XX help growth broad suite grow the From systems, approximately comprises of of needs XX%. solutions market and was market SKUs share. fit our and XXXX patient XXXX, to
breath XX in with XX, September XX-month smaller and Paragon $XXX diversified companies orthopedic foot med of both sleep compete development XX, largest million over foot company. ankle ended revenue new foot businesses.
At we product ankle and XXXX. We and believe often eat, We single as as pure with have period ankle. and play We trailing we are tech products for global large, the the well
continue improving the taking by We foot medical over ankle new and technologies and share can and time, market market world-class outcomes expand via innovative and patient we believe education.
SMART distribution; product advanced initiatives; and sales and education marketing growth long-term expanded medical to four, opportunities. five, includes: business development XX strategy new Our drive two, one, development; three, initiatives; durable
with product development. the new starting First,
launch XX. culture success proven catalyst ability is of us market innovative years. several develop for over our and to technologies, and the identify, and the with the our to has Our ankle-centric growth the passion past been Paragon combined It share cornerstone grow of foot and
that outcomes, increases clinician market and potential and driven advancements patient ankle foot the will believe in further patient growth accelerate awareness of and to we treatments. available improve has in the adoption However, technology by
and for new orthopedic a significant foot ankle the results. we on that of a the and with foot ankle more as clinician there products with focus track exclusive will result opportunity par XX increased its Given and and launches.
Paragon be segment, product believe emerging specialties ankle launching catalyst to to proven and and market is innovation patient new innovative outcomes and of orthopedic foot be on other mature improve record a young clinical improvements in a is
the the aging market to more expect and populations incidence to an of macro including increased trends, pursue a patient lifestyle. also population, We desire diabetes obesity from benefit active well as broader favorable as
initiatives outcomes. an XX SMART also of Our driver will important be improving patient
area evaluate a of us branded support, as algorithms support, key continue improve XX and such better our have technologies We a enabling SMART category, get patient to In mission postoperative planning, patient's surgeons patient-specific improve to improve data solutions, opportunities even to before patients' foot we to to we surgical tools improve intraoperative around will initiatives outcomes. is for a the lives. help with surgical-guided to to developing element, key and the element support intraoperative efficiency.
Within surgical focus products center. our in we XX. is Within a the of procedural AI has aggregation XX technologies and tools outcomes and designed can have continue preoperative SMART elements: for that understanding we they outcomes live to ankle expect or X evaluation. planning of insist developed reproducibility validate are and provide overall have preoperative needs and each evaluate collection and have procedure.
And specialized postoperative finally, SMART and
will culture to our and ankle a product build exclusively has on force. entrepreneurial the allowed us market. make we attract, foot global and to line, continue clinically-oriented retain investments to with innovative sales and significant combined Additionally, and our expand leading A force sales focused leading
primarily over significantly representatives, force the independent sales sales U.S. whom of of consists are Our has years exclusive. and several majority the last grown
September of quarter.
We accounted producing XXX selling most it approximately U.S. XXXX, in revenue late XXXX. of for United our As the XX, the in representatives, sales outside third States began included which
for our sales sell an products to through foot XX our U.S. the we And and business choice full XXXX, year-to-date opportunity of XXXX suite positioned the international innovative of for of and in to XX, be focused grow part is XX, ankle company. a in our XX, September looking and of exclusively XX% with countries. revenue.
Paragon unlimited representatives markets products boasts of not a company is foot that international ankle and multichannel contributed larger well approximately As September company both
grow continue new part agenda. to education Medical Continued a outcomes our targeted and our of of and medical strength XX a improve Paragon also strategy and to growth foot of education excellence ankle patient parts and business. be marketing important are in is key our will initiatives
dedicated Our station opened headquarters. are XXXX, used with is week team. class.
Late XXX-person a for auditorium This medical almost Denver and learning Cadaver now XX and physicians our in and in infrastructure new our every team education we Lab training facility and hands-on best commercial at a
addition, education seminars. medical virtual programs many in In offer we regional
believe the an the becoming certain ankle subsegments benefits suited arbiter products benefits the patient We our foot direct-to-patient articulate our care. for our ultimate will that as of final as surgeons. and and and for patients keeps and are initiatives with of marketing of to to initiatives of XX Digital physicians focus greater patient marketing awareness solutions approach of raise a the us market Paragon well are
foot the only exclusively require can development part the Talus Paragon otherwise In of Additive the portfolio lives XX assets us passionately to change year, an foot a acquisition important we first on or plan. a completed the the and product look foot in This world Orthopedics. of gave is our large complicated is and amputation.
In and example business for of the either fusion Paragon quarter the who acquisitions This total summary, growth ankle Finally, ankle is unique Additive and XX second patented procedure would this of patients. focused fast-growing that Spacer. FDA-approved of market. possibly certain complement future the even with good our technology. of type and of Patients
ankle initiatives market accelerate and the expect will than outcomes patients. about gains share the future better via enabled for its deliver We clinical foot by of SMART orthopedic more am ever sales future now and been have will better and develop a XX potentially drive channel, foot excited our XX Paragon ankle technologies shape in we to potential and best-in-class I I that growth and market.
revenue provide summary of turn third quarter financial who I will to it over a provide fourth XXXX. Steve, quarter Steve? performance now will the and guidance for our of
